In re Cadira Group Holdings, LLC Litigation

CourtCourt of Chancery of Delaware
DecidedJuly 12, 2021
DocketC.A. No. 2018-0616-JRS
StatusPublished

This text of In re Cadira Group Holdings, LLC Litigation (In re Cadira Group Holdings, LLC Litigation) is published on Counsel Stack Legal Research, covering Court of Chancery of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Cadira Group Holdings, LLC Litigation, (Del. Ct. App. 2021).

Opinion

IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE

IN RE CADIRA GROUP ) Consolidated HOLDINGS, LLC LITIGATION ) C.A. No. 2018-0616-JRS

MEMORANDUM OPINION

Date Submitted: April 14, 2021 Date Decided: July 12, 2021

John L. Reed, Esquire and Matthew Denn, Esquire of DLA Piper LLP (US), Wilmington, Delaware and Ardith Bronson, Esquire and Maia Sevilla-Sharon, Esquire of DLA Piper LLP (US), Miami, Florida, Attorneys for Knights Genesis Healthcare, LLC.

Raymond W. Cobb, Esquire of Law Offices of Raymond W. Cobb, LLC (formerly with O’Hagan Meyer LLP), Wilmington, Delaware and Kevin F. Berry, Esquire of O’Hagan Meyer LLP, Philadelphia, Pennsylvania, Attorneys for Beau Gertz, Perseverance Med, LLC and Cadira Group Holdings, LLC.

SLIGHTS, Vice Chancellor The parties to a healthcare joint venture have lost trust in each other and have

brought competing claims that include alleged breach of contract, fraud and breach

of fiduciary duty. In October 2017, Beau Gertz presented a business opportunity to

representatives of Knights Genesis Healthcare, LLC (“KGH”) to partner with his

company, Perseverance Med, LLC (“Perseverance”), in forming a vehicle that

would make targeted investments in the healthcare field. This led to the creation of

Cadira Group Holdings, LLC (“Cadira”), a joint venture operating as the parent

company to a number of already-existing and to-be-formed healthcare-related

companies. According to KGH, Gertz assured KGH that he had already built a

successful healthcare business platform among the operating subsidiaries that were

to be rolled into the joint venture and represented that he had the experience and

business integrity to build on that success. KGH now says those assurances and

representations were false.

Following closing on the joint venture, in July 2018, KGH received word that

Cadira and Gertz had been sued in Missouri by at least 25 health insurance

companies, each of which alleged Gertz and Cadira’s subsidiaries were engaged in

widespread healthcare fraud. Less than a month later, KGH initiated this litigation

in which it seeks rescission of the agreements that created Cadira and damages

resulting from Gertz’s alleged fraudulent inducement, breach of Cadira’s operating

agreement, unjust enrichment and breaches of fiduciary duty. Cadira, Perseverance

1 and Gertz (the “Cadira Parties”) have moved to dismiss those claims under Court of

Chancery Rule 12(b)(6).

Cadira has filed its own complaint against KGH for breaches of the parties’

joint venture agreements in which it seeks declaratory relief and a decree that KGH

must specifically perform its obligation to provide funding to Cadira.1 KGH has

moved to dismiss that complaint, also under Rule 12(b)(6) as well as Rule 12(b)(1).

For reasons explained below, the Cadira Parties’ bid to dismiss KGH’s

complaint fails. KGH has pled fraud with particularity, has well pled that Gertz’s

dissipation of Cadira assets without proper approval breached the operative

agreement governing his conduct as manager of the joint venture and has well pled

unjust enrichment as an alternative to breach of contract.

Cadira’s complaint likewise survives dismissal. Its claims for breach of

contract and related relief sufficiently plead the occurrence of conditions precedent

(albeit barely) and this Court has subject matter jurisdiction to adjudicate its claims.

I. BACKGROUND

I have drawn the facts from well-pled allegations in KGH’s Verified First

Amended Complaint (the “KGH Complaint”) and Cadira’s Verified First Amended

Complaint (the “Cadira Complaint”), as well as documents incorporated by

1 As discussed below, the competing actions have been consolidated by stipulation of the parties.

2 reference or integral to those pleadings. 2 For purposes of each motion to dismiss,

I accept as true each Complaint’s well-pled factual allegations and draw all

reasonable inferences in favor of the nonmoving party.3

A. Parties

Cadira is a Delaware LLC created on or about February 1, 2018, to serve as

the parent company for multiple healthcare-related entities.4 KGH, a Delaware

LLC, is the 49% owner of Cadira. 5 Beau Gertz is the sole manager of Cadira and

controller of Perseverance.6 Perseverance is a Colorado LLC that controls at least

51% of Cadira. 7

2 KGH’s Verified Am. Compl. (“KGH Compl.”) (D.I. 14) (filed in Consol. Action No. 2018-0616-JRS); Cadira’s Verified Am. Compl., Cadira Hldgs. Gp., LLC vs. Knight’s Genesis Healthcare, LLC, C.A. 2018-0877-JRS (“Cadira Compl.”) (D.I. 3); Wal-Mart Stores, Inc. v. AIG Life Ins. Co., 860 A.2d 312, 320 (Del. 2004) (noting that on a motion to dismiss, the Court may consider documents that are “incorporated by reference” or “integral” to the complaint). Unless specific reference is made to C.A. 2018-0877-JRS, all case documents can be found in the docket for the consolidated action. 3 Savor, Inc. v. FMR Corp., 812 A.2d 894, 896–97 (Del. 2002). 4 KGH Compl. ¶¶ 10, 14, 27. 5 KGH Compl. ¶ 6. I note that this is contested by the Cadira Parties, who argue that the plain terms of Cadira’s operating agreement establish that KGH never became a member of Cadira. Cadira Parties’ Opening Br. in Supp. of Mot. to Dismiss KGH’s Compl. (“Cadira OB”) (D.I. 15) at 30–32; Cadira Compl. ¶¶ 34, 51, 56. 6 KGH Compl. ¶¶ 7, 9; Cadira Compl. ¶ 25. 7 KGH Compl. ¶ 8.

3 B. The Parties Form Their Joint Venture

In October 2017, representatives of KGH, Feng Li and Vincent Xie, were

introduced to Gertz through a mutual acquaintance. 8 The parties held a formal

meeting on October 6, 2017, during which Gertz proposed that the parties form a

joint venture (the “October 6 Meeting”).9 Specifically, Gertz proposed that Li and

Xie, acting through KGH, and Gertz, acting through Perseverance, create a new

entity, Cadira, “in pursuit of lucrative business opportunities in the healthcare

sector.”10 Under this arrangement, Cadira would be the parent entity for several

companies controlled by Perseverance that were already operating in the healthcare

sector, including Serodynamics.11 Gertz made clear through his presentation that

he, Perseverance and Cadira would “always operate with the highest degree of

integrity, in complete compliance with the law, with medical ethics and with respect

to the dignity of all we serve.” 12 He also indicated that the companies under the

8 KGH Compl. ¶ 13; Cadira Compl. ¶ 6. 9 KGH Compl. ¶ 14; Cadira Compl. ¶¶ 7–9. 10 KGH Compl. ¶ 14; Cadira Compl. ¶¶ 8–9. 11 KGH Compl. ¶ 14; Cadira Compl. ¶ 9. 12 KGH Compl. ¶ 16; Cadira Compl. ¶ 11.

4 Perseverance umbrella that were to become Cadira’s subsidiaries (if KGH invested)

had realized net profits exceeding $27 million from 2016 to 2017. 13

In December 2017, Gertz informed KGH of a unique opportunity to acquire a

distressed rural hospital in Cedarville, California called the Surprise Valley Hospital

(“Surprise Valley”).14 This led to the December 22, 2017 “Memorandum of

Understanding” between KGH and Cadira, summarizing the proposal to acquire

Surprise Valley.15

C. The Joint Venture Agreements

To formalize the acquisition of Surprise Valley and KGH’s general interest in

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Glaski v. Bank of America CA5
218 Cal. App. 4th 1079 (California Court of Appeal, 2013)
Victaulic Co. v. Tieman
499 F.3d 227 (Third Circuit, 2007)
Airborne Health, Inc. v. Squid Soap, LP
984 A.2d 126 (Court of Chancery of Delaware, 2009)
McMullin v. Beran
765 A.2d 910 (Supreme Court of Delaware, 2000)
Bailey v. City of Wilmington
766 A.2d 477 (Supreme Court of Delaware, 2001)
Abry Partners V, L.P. v. F & W Acquisition LLC
891 A.2d 1032 (Court of Chancery of Delaware, 2006)
Emerald Partners v. Berlin
726 A.2d 1215 (Supreme Court of Delaware, 1999)
At&T CORP. v. Lillis
953 A.2d 241 (Supreme Court of Delaware, 2008)
Brehm v. Eisner
746 A.2d 244 (Supreme Court of Delaware, 2000)
Savor, Inc. v. FMR Corp.
812 A.2d 894 (Supreme Court of Delaware, 2002)
E.I. duPont De Nemours & Co. v. Florida Evergreen Foliage
744 A.2d 457 (Supreme Court of Delaware, 1999)
Nemec v. Shrader
991 A.2d 1120 (Supreme Court of Delaware, 2010)
Anglo American Security Fund, L.P. v. S.R. Global International Fund, L.P.
829 A.2d 143 (Court of Chancery of Delaware, 2003)
Allied Capital Corp. v. GC-Sun Holdings, L.P.
910 A.2d 1020 (Court of Chancery of Delaware, 2006)
VLIW TECHNOLOGY, LLC v. Hewlett-Packard Co.
840 A.2d 606 (Supreme Court of Delaware, 2003)
Gaffin v. Teledyne, Inc.
611 A.2d 467 (Supreme Court of Delaware, 1992)
In Re Walt Disney Co. Derivative Litigation
906 A.2d 27 (Supreme Court of Delaware, 2006)
Fleer Corp. v. Topps Chewing Gum, Inc.
539 A.2d 1060 (Supreme Court of Delaware, 1988)
Wal-Mart Stores, Inc. v. AIG Life Insurance
860 A.2d 312 (Supreme Court of Delaware, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
In re Cadira Group Holdings, LLC Litigation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-cadira-group-holdings-llc-litigation-delch-2021.